Resources
43 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 12/20/2021 (updated 3/26/2024)
The Centers for Disease Control and Prevention (CDC) want greater awareness of adverse childhood experiences (ACEs) and their connection to high rates of overdose and suicide. This week they announced a new training webpage, UrgentRelatedPreventable.org, designed in collaboration with the American Public Health Association to provide background and talking points. The site explains how exposure to certain events and conditions in childhood have lasting effects on health, well-being, and prosperity far into adulthood. See Funding section below for a CDC effort to research the links between ACEs and substance use.
Posted 8/8/2023 (updated 3/26/2024)
This webinar is an invaluable opportunity for health care professionals, policymakers, researchers, and anyone else interested in mental health and substance use interventions to learn about the latest research and innovative approaches in the field.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/14/2022 (updated 3/27/2024)
Substance use and its progression to impairment, loss of control, and development of substance use disorders is a significant problem for adolescents and young adults. This presentation will provide an overview of developmentally-informed approaches to engaging youth and their families in treatment.
Learning Objectives:
Recognize motivational approaches to working with substance involved youth
Identify approaches to engaging families of substance involved youth
Speaker: Marc Fishman, MD
Posted 5/10/2022 (updated 3/27/2024)
Fentanyl is a synthetic opioid typically used to treat patients with chronic severe pain or severe pain following surgery. Fentanyl is a Schedule II controlled substance that is similar to morphine but about 100 times more potent. Under the supervision of a licensed medical professional, fentanyl has a legitimate medical use. Patients prescribed fentanyl should be monitored for potential misuse or abuse.
Posted 5/11/2022 (updated 3/27/2024)
The rate of drug overdose deaths in the USA has more than tripled since the turn of the century, and rates are disproportionately high among the American Indian/Alaska Native (AI/AN) population. Little is known about the overall historical trends in AI/AN opioid-only and opioid/polysubstance-related mortality. This study will address this gap.
Posted 7/25/2022 (updated 3/27/2024)
The interactive graphics allow readers to explore how the crisis of overdose deaths involving opioid use has not only grown in magnitude since 2000, but has also changed in character.
Posted 7/25/2022 (updated 3/27/2024)
Researchers used claims and enrollment data from Tennessee’s Medicaid program to develop an algorithm measuring five types of ACEs: maltreatment and peer violence, foster care and family disruption, maternal mental illness, maternal substance use disorder, and abuse of the mother. Recent recommendations from the National Advisory Committee on Rural Health & Human Services included stronger data collection that analyzes rural-urban differences.
Posted 8/23/2022 (updated 3/27/2024)
This observational study of 719 612 pharmacy claims data shows that OOP costs of naloxone grew substantially beginning in 2016. However, OOP costs did not increase for all patients and all brands of naloxone but primarily for uninsured patients and for the Evzio brand. The findings suggest that the OOP cost of naloxone has been an increasingly substantial barrier to naloxone access for uninsured patients, a population that constitutes nearly one-fifth of adults with opioid use disorder.